Biovie Inc.
About
1.42USD-0.02 -1.39%
Closed • Updated at 04:05 GMT+00:00Market Cap$10.71M
Volume33.5K
Beta0.46
RSI47.95
Biovie Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 27 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 26 2026
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 18 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 6 2026
Bioventus Reports First Quarter Financial Results
Apr 27 2026
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
Recent Videos
Virtual KOL Event to Discuss Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease
May 29, 2026
CEO Cuong Do on BioVie's (Nasdaq: BIVI) $10B+ Drug Candidate & Two Imminent Readouts
May 27, 2026
BioVie Completes Long COVID Trial Enrollment With Data Expected This Summer
May 27, 2026
BioVie Completes Long COVID Trial Enrollment With Data Expected This Summer
May 27, 2026
Community Chat
Ask AI
Try asking